請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16968
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳水田 | |
dc.contributor.author | Ting-Fang Lo | en |
dc.contributor.author | 羅庭芳 | zh_TW |
dc.date.accessioned | 2021-06-07T23:51:14Z | - |
dc.date.copyright | 2014-03-18 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-01-21 | |
dc.identifier.citation | References
1. MATO JM, CORRALES FJ, Lu SC, AVILA MA (2002) S-Adenosylmethionine: a control switch that regulates liver function. The FASEB journal 16: 15-26. 2. Mato JM, Lu SC (2007) Role of S‐adenosyl‐L‐methionine in liver health and injury. Hepatology 45: 1306-1312. 3. Kotb M, Mudd SH, Mato JM, Geller AM, Kredich NM, et al. (1997) Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends in genetics: TIG 13: 51. 4. Mato JM, Alvarez L, Ortiz P, Pajares MA (1997) S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 73: 265-280. 5. LeGros HL, Jr., Halim AB, Geller AM, Kotb M (2000) Cloning, expression, and functional characterization of the beta regulatory subunit of human methionine adenosyltransferase (MAT II). J Biol Chem 275: 2359-2366. 6. Cai J, Mao Z, Hwang J-J, Lu SC (1998) Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer research 58: 1444-1450. 7. Lu SC, Mato JM (2008) S‐Adenosylmethionine in cell growth, apoptosis and liver cancer. Journal of gastroenterology and hepatology 23: S73-S77. 8. Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, et al. (2012) Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 56: 165-175. 9. Huang Z-Z, Mao Z, Cai J, Lu SC (1998) Changes in methionine adenosyltransferase during liver regeneration in the rat. American Journal of Physiology-Gastrointestinal and Liver Physiology 275: G14-G21. 10. Huang ZZ, Mato JM, Kanel G, Lu SC (1999) Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. Hepatology 29: 1471-1478. 11. Paneda C, Gorospe I, Herrera B, Nakamura T, Fabregat I, et al. (2002) Liver cell proliferation requires methionine adenosyltransferase 2A mRNA up‐regulation. Hepatology 35: 1381-1391. 12. Garcea R, Daino L, Pascale R, Simile MM, Puddu M, et al. (1989) Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. Cancer research 49: 1850-1856. 13. Martinez-Chantar ML, Corrales FJ, MARTINEZ-CRUZ A, Garcia-Trevijano ER, Huang Z-Z, et al. (2002) Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. The FASEB journal 16: 1292-1294. 14. Yang H, Sadda MR, Li M, Zeng Y, Chen L, et al. (2004) S‐adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl‐xS. Hepatology 40: 221-231. 15. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, et al. (2003) Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. 16. Liu Q, Wu K, Zhu Y, He Y, Wu J, et al. (2007) Silencing MAT2A gene by RNA interference inhibited cell growth and induced apoptosis in human hepatoma cells. Hepatology Research 37: 376-388. 17. Wang Q, Liu QY, Liu ZS, Qian Q, Sun Q, et al. (2008) Inhibition of hepatocelluar carcinoma MAT2A and MAT2beta gene expressions by single and dual small interfering RNA. J Exp Clin Cancer Res 27: 72. 18. Ramani K, Yang H, Xia M, Ara AI, Mato JM, et al. (2008) Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2β. Hepatology 47: 521-531. 19. Wang Q, Liu Q-Y, Liu Z-S, Qian Q, Sun Q, et al. (2008) Lentivirus mediated shRNA interference targeting MAT2B induces growth-inhibition and apoptosis in hepatocellular carcinoma. World journal of gastroenterology: WJG 14: 4633. 20. Imanshahidi M, Hosseinzadeh H (2008) Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22: 999-1012. 21. Amin A, Subbaiah T, Abbasi K (1969) Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Canadian journal of microbiology 15: 1067-1076. 22. Kuo C-L, Chi C-W, Liu T-Y (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer letters 203: 127-137. 23. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264. 24. Sun Y, Xun K, Wang Y, Chen X (2009) A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anti-cancer drugs 20: 757-769. 25. Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, et al. (2000) Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer letters 148: 19-25. 26. Mantena SK, Sharma SD, Katiyar SK (2006) Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Molecular cancer therapeutics 5: 296-308. 27. Peng P-L, Hsieh Y-S, Wang C-J, Hsu J-L, Chou F-P (2006) Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicology and applied pharmacology 214: 8-15. 28. Kim S, Choi JH, Kim JB, Nam SJ, Yang J-H, et al. (2008) Berberine suppresses TNF-α-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules 13: 2975-2985. 29. Wang L, Cao H, Lu N, Liu L, Wang B, et al. (2013) Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells. PloS one 8: e56666. 30. Wang L, Liu L, Shi Y, Cao H, Chaturvedi R, et al. (2012) Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor. PloS one 7: e36418. 31. Liu B, Wang G, Yang J, Pan X, Yang Z, et al. (2011) Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PloS one 6: e21416. 32. Auyeung KK-W, Ko JK-S (2009) Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. International journal of molecular medicine 24: 571-577. 33. Tang J, Feng Y, Tsao S, Wang N, Curtain R, et al. (2009) Berberine and Coptidis Rhizoma as novel antineoplastic. Journal of ethnopharmacology 126: 5-17. 34. Hwang J-M, Kuo H-C, Tseng T-H, Liu J-Y, Chu C-Y (2006) Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Archives of toxicology 80: 62-73. 35. Wang N, Feng Y, Zhu M, Tsang CM, Man K, et al. (2010) Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular biochemistry 111: 1426-1436. 36. Ma C, Tang K, Liu Q, Zhu R, Cao Z (2013) Calmodulin as a potential target by which berberine induce cell cycle arrest in human hepatoma Bel7402 cells. Chemical biology & drug design. 37. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355. 38. Hwang H, Mendell J (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. British journal of cancer 94: 776-780. 39. Jansson MD, Lund AH (2012) MicroRNA and cancer. Molecular oncology. 40. Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis 33: 1126-1133. 41. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840. 42. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63. 43. Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature cell biology 11: 228-234. 44. Azuma-Mukai A, Oguri H, Mituyama T, Qian ZR, Asai K, et al. (2008) Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing. Proceedings of the National Academy of Sciences 105: 7964-7969. 45. Okamura K, Phillips MD, Tyler DM, Duan H, Chou Y-t, et al. (2008) The regulatory activity of microRNA* species has substantial influence on microRNA and 3′ UTR evolution. Nature structural & molecular biology 15: 354-363. 46. Goff LA, Davila J, Swerdel MR, Moore JC, Cohen RI, et al. (2009) Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One 4: e7192. 47. Guo L, Lu Z (2010) The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One 5: e11387. 48. Okamura K, Chung W-J, Lai EC (2008) The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs. Cell Cycle 7: 2840-2845. 49. Yang J-S, Phillips MD, Betel D, Mu P, Ventura A, et al. (2011) Widespread regulatory activity of vertebrate microRNA* species. Rna 17: 312-326. 50. LIU X-y, ZHANG L, ZHANG Y, YANG J-m (2012) Roles of eEF-2 kinase in cancer. Chinese Medical Journal 125: 2908-2913. 51. Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, et al. (2011) MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharmaceutics & drug disposition 32: 355-367. 52. Yokoi T, Nakajima M (2013) microRNAs as Mediators of Drug Toxicity. Annual review of pharmacology and toxicology 53: 377-400. 53. Martinez-Sanchez A, Murphy CL (2013) MicroRNA Target Identification—Experimental Approaches. Biology 2: 189-205. 54. Betel D, Koppal A, Agius P, Sander C, Leslie C (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology 11: R90. 55. Zhu M, Wang N, Tsao S-W, Yuen M-F, Feng Y, et al. (2011) Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract. Experimental and Therapeutic Medicine 2: 27. 56. Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, et al. (2013) Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin 34: 157-166. 57. Braig S, Bosserhoff A (2012) Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene 32: 837-848. 58. Venook AP, Papandreou C, Furuse J, de Guevara LL (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncologist 15: 5-13. 59. YANG H, HUANG Z-Z, WANG J, LU SC (2001) The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. The FASEB journal 15: 1507-1516. 60. Rodriguez JL, Boukaba A, Sandoval J, Georgieva EI, Latasa MU, et al. (2007) Transcription of the MAT2A gene, coding for methionine adenosyltransferase, is up-regulated by E2F and Sp1 at a chromatin level during proliferation of liver cells. Int J Biochem Cell Biol 39: 842-850. 61. LeGros L, Halim AB, Chamberlin ME, Geller A, Kotb M (2001) Regulation of the human MAT2B gene encoding the regulatory beta subunit of methionine adenosyltransferase, MAT II. J Biol Chem 276: 24918-24924. 62. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer research 65: 7065-7070. 63. MOLLOY A (2011) Bioinformatic and Genetic Association Analysis of MicroRNA Target Sites in One-Carbon Metabolism Genes. 64. Yan GR, Xu SH, Tan ZL, Liu L, He QY (2011) Global identification of miR‐373‐regulated genes in breast cancer by quantitative proteomics. Proteomics 11: 912-920. 65. Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, et al. (2012) Nonalcoholic Fatty Liver in Children and Adolescents: An Overview. Journal of Adolescent Health. 66. Farrell GC, Wong VW-S, Chitturi S (2013) NAFLD in Asia—as common and important as in the West. Nature Reviews Gastroenterology and Hepatology. 67. Angulo P (2008) Obesity and nonalcoholic fatty liver disease. Nutrition reviews 65: S57-S63. 68. Torres DM, Williams CD, Harrison SA (2012) Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 69. Nugent C, Younossi ZM (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nature Clinical Practice Gastroenterology & Hepatology 4: 432-441. 70. Fabbrini E, Sullivan S, Klein S (2009) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679-689. 71. Anderson N, Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacological reviews 60: 311-357. 72. Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, et al. (2000) The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci U S A 97: 1444-1449. 73. Kim K-H (1997) Regulation of mammalian acetyl-coenzyme A carboxylase. Annual review of nutrition 17: 77-99. 74. Abu-Elheiga L, Almarza-Ortega DB, Baldini A, Wakil SJ (1997) Human acetyl-CoA carboxylase 2 molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. Journal of Biological Chemistry 272: 10669-10677. 75. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, et al. (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366-1374. 76. Cases S, Stone SJ, Zhou P, Yen E, Tow B, et al. (2001) Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. Journal of Biological Chemistry 276: 38870-38876. 77. Yen C-LE, Stone SJ, Koliwad S, Harris C, Farese RV (2008) Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. Journal of lipid research 49: 2283-2301. 78. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, et al. (2005) Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371. 79. Anis K, Rajeshkumar N, Kuttan R (2001) Inhibition of chemical carcinogenesis by berberine in rats and mice. Journal of pharmacy and pharmacology 53: 763-768. 80. Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature medicine 10: 1344-1351. 81. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, et al. (2008) Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biological and Pharmaceutical Bulletin 31: 1169-1176. 82. Choi B, Ahn I, Kim Y, Park J, Lee S, et al. (2006) Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Experimental and molecular medicine 38: 599. 83. Hu Y, Davies GE (2010) Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 81: 358-366. 84. Zhou J, Zhou S (2010) Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. European journal of pharmacology 649: 390-397. 85. Li G-S, Liu X-H, Zhu H, Huang L, Liu Y-L, et al. (2011) Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biological and Pharmaceutical Bulletin 34: 644-654. 86. Chang X, Yan H, Fei J, Jiang M, Zhu H, et al. (2010) Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. Journal of lipid research 51: 2504-2515. 87. Jin H, Tuo W, Lian H, Liu Q, Zhu X-Q, et al. (2010) Strategies to identify microRNA targets: new advances. N Biotechnol 27: 734-738. 88. Mo Y-Y (2012) MicroRNA regulatory networks and human disease. Cellular and Molecular Life Sciences: 1-3. 89. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-U38. 90. Guo HL, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-U866. 91. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773. 92. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63. 93. Nakanishi N, Nakagawa Y, Tokushige N, Aoki N, Matsuzaka T, et al. (2009) The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochemical and biophysical research communications 385: 492-496. 94. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ (2011) MicroRNAs in lipid metabolism. Curr Opin Lipidol 22: 86-92. 95. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C (2011) The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annual review of nutrition 31: 49-63. 96. Rayner KJ, Fernandez-Hernando C, Moore KJ (2012) MicroRNAs regulating lipid metabolism in atherogenesis. Thromb Haemost 107: 642-647. 97. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, et al. (2012) MicroRNA‐27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 98. Wen J, Friedman JR (2012) miR-122 regulates hepatic lipid metabolism and tumor suppression. The Journal of clinical investigation: 1. 99. Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y (2005) Mutations in the holocarboxylase synthetase gene HLCS. Human mutation 26: 285-290. 100. Hassan YI, Zempleni J (2008) A novel, enigmatic histone modification: biotinylation of histones by holocarboxylase synthetase. Nutrition reviews 66: 721-725. 101. Chakrabarti P, English T, Shi J, Smas CM, Kandror KV (2010) Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 59: 775-781. 102. Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Current Biology 19: R1046-R1052. 103. Lamming DW, Sabatini DM (2013) A Central Role for mTOR in Lipid Homeostasis. Cell metabolism 18: 465-469. 104. Hart SN, Li Y, Nakamoto K, Subileau E-a, Steen D, et al. (2010) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metabolism and Disposition 38: 988-994. 105. Lo T-F, Tsai W-C, Chen S-T (2013) MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and Inhibits Hepatoma Cell Growth. PloS one 8: e75628. 106. Hinson ER, Cresswell P (2009) The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic α-helix. Proceedings of the National Academy of Sciences 106: 20452-20457. 107. Okamoto Y, Tanaka S, Haga Y (2002) Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatology research 23: 138-144. 108. Da Wei Huang BTS, Lempicki RA (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4: 44-57. 109. Kochan G, Pilka ES, von Delft F, Oppermann U, Yue WW (2009) Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme A synthetase ACSM2A. Journal of molecular biology 388: 997-1008. 110. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, et al. (2010) Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. Journal of Clinical Endocrinology & Metabolism 95: 3039-3047. 111. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, et al. (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. The American journal of gastroenterology 103: 1372-1379. 112. Miserez AR, Cao G, Probst LC, Hobbs HH (1997) Structure of the Human Gene Encoding Sterol Regulatory Element Binding Protein 2 (< i> SREBF2</i>). Genomics 40: 31-40. 113. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA. org resource: targets and expression. Nucleic Acids Research 36: D149-D153. 114. Kruger J, Rehmsmeier M (2006) RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Research 34: W451-W454. 115. Flowers E, Froelicher ES, Aouizerat BE (2013) MicroRNA regulation of lipid metabolism. Metabolism 62: 12-20. 116. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, et al. (2007) Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. International journal of molecular medicine 20: 351-358. 117. Postic C, Girard J (2008) The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes & metabolism 34: 643-648. 118. Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology-Gastrointestinal and Liver Physiology 290: G852-G858. 119. Abu-Elheiga L, Wu H, Gu Z, Bressler R, Wakil SJ (2012) Acetyl-CoA carboxylase 2−/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. Journal of Biological Chemistry 287: 12578-12588. 120. Liu Y, Zhang L, Song H, Ji G (2013) Update on Berberine in Nonalcoholic Fatty Liver Disease. Evidence-Based Complementary and Alternative Medicine 2013. 121. Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351. 122. Zhao H-L, Sui Y, Qiao C-F, Yip KY, Leung RK, et al. (2012) Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 61: 933-943. 123. Hu Y, Davies GE (2010) Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 81: 358-366. 124. Ruderman N, Prentki M (2004) AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature Reviews Drug Discovery 3: 340-351. 125. Kim J, Kundu M, Viollet B, Guan K-L (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature cell biology 13: 132-141. 126. Imai S (2009) Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 15: 20-28. 127. Guarente L (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874. 128. Shi Y, Burn P (2004) Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nature Reviews Drug Discovery 3: 695-710. 129. Savage DB, Choi CS, Samuel VT, Liu Z-X, Zhang D, et al. (2006) Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. Journal of Clinical Investigation 116: 817-824. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16968 | - |
dc.description.abstract | 小檗鹼 (berberine) 是一種異喹啉類生物鹼,具有廣泛的藥用效果,包含了抗癌和降低脂肪的效果。我們利用微小 RNA 的微陣列晶片發現, 人類肝癌細胞株 (HepG2) 以及人類初代肝細胞 (primary human hepatocytes) 在經小檗鹼處理後,miR-21-3p (從前命名為 miR-21*) 之表現量上升。在論文的第一個部分,我們證明 miR-21-3p 會調控甲硫胺酸腺基轉移酵素 (methionine adenosyltransferase, 簡稱 MAT) 之表現並抑制肝癌細胞生長。 MAT 是細胞內的酵素,負責合成 S-腺甘甲硫酸胺 (S-adenosylmethionine, 簡稱 SAM),SAM 是生物上主要的甲基供應來源,可調控肝細胞的增生、死亡及分化。MAT1A 和 MAT2A 兩個基因編碼出兩個不同的 MAT 催化 isoform。第三個基因,MAT2B 則是編碼出 MAT2A 的調控單元。在肝癌中, MAT1A 負調控且 MAT2A 正調控的現象會發生,這個現象被稱為 MAT1A:MAT2A 轉換。這個轉換的過程伴隨著 MAT2B 表現量上升,最後導致 SAM 濃度下降並加速癌症細胞的生長。我們發現 miR-21-3p 可藉由其種子序列直接和 MAT2A 及 MAT2B 之3’非編碼區(3’UTR) 配對,抑制MAT2A 及 MAT2B 之表現。此外,過量表現 miR-21-3p 後,肝癌細胞內之 SAM 濃度會上升,而 SAM 濃度上升已經被證實是不利於肝癌細胞生長的。我們亦證實 miR-21-3p 過量表現,會抑制肝癌細胞生長且誘導細胞凋亡。以上結果指出, miR-21-3p 在肝癌細胞中有腫瘤抑制的功能並具有治療的潛力。 在論文的第二個部分,我們證明 miR-21-3p 會調控脂肪代謝相關基因進而降低肝細胞內脂肪的含量。非酒精性脂肪肝是病理性脂肪油滴 (主成分為三酸甘油脂) 累積在肝細胞中的疾病,在人類日漸過重以及肥胖的趨勢之下,非酒精性脂肪肝已經成為了普遍的肝臟疾病之一。我們發現 miR-21-3p 可使人類初代肝細胞內的脂肪油滴含量下降至控制組的 40% ~44%;且可使 in vitro 油酸誘導之脂肪肝疾病模式細胞內的脂肪油滴含量下降至控制組的 50% ~58%。我們驗證了 miR-21-3p 可抑制乙醯輔酶 A 羧化酵素 1 (acetyl-CoA carboxylase alpha, ACACA; 是脂肪合成的第一個速率決定步驟) 及乙醯輔酶 A 羧化酵素2 (acetyl-CoA carboxylase beta, ACACB; 是脂肪氧化的關鍵負調控酵素) 之表現量,而造成表現下降的機制為造成ACACA mRNA的不穩定與藉由種子序列針對 ACACB 的外顯子 23 配對。此外,miR-21-3p 藉由其種子序列直接和 DGAT2 之3’ UTR 配對,抑制二脂酰甘油酰基轉移酶 2 (diglyceride acyltransferase 2, DGAT2; 是三酸甘油酯生合成路徑的最後一個且是唯一的速率決定步驟) 之表現。我們亦發現 miR-21-3p會降低人類初代肝細胞內脂肪合成相關基因的表現,如HLCS、MTOR、RPTOR。綜合以上結果,我們證明了 miR-21-3p 可減少肝臟脂肪生合成、促進脂肪氧化,進而對減緩脂肪肝。 | zh_TW |
dc.description.abstract | Berberine, an isoquinoline alkaloid, has a wide range of pharmacological effects including anti-cancer and lipid-lowering effects. We used microRNA microarrays to find that the expression level of miR-21-3p (previously named miR-21*) increased after berberine treatment in the HepG2 human hepatoma cell line and in primary human hepatocytes (PHHs). In the first part of the dissertation, we show that miR-21-3p regulated methionine adenosyltransferase (MAT) and inhibited hepatoma cell growth. MAT is the cellular enzyme that catalyzes the synthesis of S-adenosylmethionine (SAM), the principal biological methyl donor and a key regulator of hepatocyte proliferation, death and differentiation. Two genes, MAT1A and MAT2A, encode 2 distinct catalytic MAT isoforms. A third gene, MAT2B, encodes a MAT2A regulatory subunit. In hepatocellular carcinoma (HCC), MAT1A downregulation and MAT2A upregulation occur, known as the MAT1A:MAT2A switch. The switch is accompanied with an increasing expression of MAT2B, which results in decreased SAM levels and facilitates cancer cell growth. Our findings provide the first evidence that miR-21-3p directly reduces the expression of MAT2A and MAT2B by targeting their 3' UTRs. In addition, an overexpression of miR-21-3p increased intracellular SAM contents, which have been proven to be a growth disadvantage for hepatoma cells. The overexpression of miR-21-3p suppresses growth and induces apoptosis in HepG2 cells. Overall, our results demonstrate that miR-21-3p functions as a tumor suppressor by directly targeting both MAT2A and MAT2B, indicating its therapeutic potential in HCC. In the second part of the dissertation, we show that miRNA-21-3p regulated lipid metabolism genes to reduce fat content in hepatocytes. Nonalcoholic fatty liver disease, which results from the accumulation of pathological lipid droplets in hepatocytes (primarily in triacylglycerol) is rapidly becoming a common liver disease because of the growing prevalence of overweight and obesity. Here we found that miR-21-3p caused a decrease in lipid droplet content in PHHs amongst the control group (from 40% to 44%), and in an oleic acid-induced in vitro fatty liver disease model (from 50% to 58%). We verified that miR-21-3p reduced the expression of acetyl-CoA carboxylase alpha (ACACA; the first rate-limiting step of fatty acid synthesis) and acetyl-CoA carboxylase beta (ACACB; the key negative regulator of fatty acid oxidation) by destabilising ACACA mRNA and targeting the exon 23 of ACACB, respectively. In addition, miR-21-3p directly reduced the expression of diglyceride acyltransferase 2 (DGAT2; the terminal and only committed enzyme in the biosynthesis of triacylglycerol) by targeting its 3' UTRs. Furthermore, miR-21-3p decreased the expression of fatty acid biosynthesis-related genes such as HLCS, MTOR, and RPTOR in PHHs. These findings demonstrate that miR-21-3p can alleviate fatty liver disease by reducing hepatic lipogenesis and promoting lipid oxidation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T23:51:14Z (GMT). No. of bitstreams: 1 ntu-103-D98b46002-1.pdf: 4323025 bytes, checksum: b5a8fef2b8369f1c427f810bfc349c15 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 謝誌 i
中文摘要 ii 英文摘要 iv 目錄 vi Abbreviations xii List of Figures xiii List of Tables xv Chapter 1 MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth 1.1 Introduction 1.1.1 Methionine adenosyltransferase (MAT) 1 1.1.2 MAT1A:MAT2A switch in hepatocellular carcinoma 1 1.1.3 Berberine and its anti-cancer effect 2 1.1.4 MicroRNA and microRNA* 3 1.1.5 Experimental approaches and summary 4 1.2 Materials and Methods 1.2.1 Cell culture and treatment 6 1.2.2 RNA isolation 6 1.2.3 Microarray 7 1.2.4 Quantitative real-time RT-PCR (qRT-PCR) 8 1.2.5 Argonaute immunoprecipitation assay 9 1.2.6 Transfection of microRNA mimics and inhibitors 9 1.2.7 Western blotting 10 1.2.8 Construction of the luciferase reporter plasmids 11 1.2.9 Mutagenesis 11 1.2.10 Dual luciferase reporter assay 12 1.2.11 Measurement of intracellular SAM concentration 13 1.2.12 Cell proliferation assay 14 1.2.13 Detection of apoptosis by using flow cytometry 14 1.3 Results 1.3.1 Increased miR-21-3p expression after berberine treatment in HepG2 cell lines 15 1.3.2 Multiple species alignments show that miR-21-3p is conserved over the mammalian evolution 19 1.3.3 MicroRNA-21-3p target prediction and validation 20 1.3.4 MicroRNA-21-3p reduces the expression of methionine adenosyltransferases 2A and 2B 23 1.3.5 MicroRNA-21-3p up-regulates intracellular SAM contents in hepatoma cells 26 1.3.6 MAT2A and MAT2B are direct targets of miR-21-3p 27 1.3.7 MicroRNA-21-3p suppresses growth and induces apoptosis in hepatoma cells 30 1.4 Discussion 1.4.1 The functions of berberine-induced miR-21-3p 32 1.4.2 MicroRNA-21-3p regulates hepatic methionine adenosyltransferase 33 1.5 Conclusion 37 Chapter 2 MicroRNA-21-3p regulates lipid metabolism genes to reduce fat content in hepatocytes 2.1 Introduction 2.1.1 Nonalchoholic fatty liver disease 38 2.1.2 Acetyl-CoA-carboxylase 39 2.1.3 Diglyceride acyltransferase 40 2.1.4 Berberine and its lipid-lowering effect 41 2.1.5 MicroRNAs in lipid metabolism 42 2.1.6 Holocarboxylase synthetase (HLCS) 43 2.1.7 MTOR, RPTOR, and mTOR complex 1 43 2.1.8 Experimental approaches and summary 44 2.2 Materials and Methods 2.2.1 Cell culture and treatment 46 2.2.2 microRNA and mRNA expression profiling 47 2.2.3 RNA isolation and quantitative real-time RT-PCR 48 2.2.4 Transfection of microRNA mimics and inhibitors 48 2.2.5 Immunoblotting 48 2.2.6 Reporter constructs preparation 49 2.2.7 Dual luciferase reporter assay 50 2.2.8 mRNA stability assay 51 2.2.9 Detection of intracellular lipid droplets by using flow cytometry 51 2.2.10 Measurement of intracellular malonyl-CoA concentration 52 2.2.11 Statistical analysis 52 2.3 Results 2.3.1 The miR-21-3p expression is consistently increased after berberine treatment in primary human hepatocytes among the three donors 54 2.3.2 MicroRNA-21-3p reduces intracellular lipid droplets in hepatocytes 56 2.3.3 Expression of lipid metabolic genes are regulated by berberine in primary human hepatocytes 59 2.3.4 MicroRNA-21-3p reduces ACACA and ACACB expression leading to decrease of intracellular malonyl-CoA concentrations 67 2.3.5 MicroRNA-21-3p reduces acetyl-CoA carboxylase gene expression by targeting to ACACB exon 23 and destabilization of ACACA mRNA 70 2.3.6 MicroRNA-21-3p down-regulates DGAT2 by directly targeting its 3’ UTRs 73 2.3.7 Lipid metabolic genes are regulated by miR-21-3p in primary human hepatocytes 76 2.4 Discussion 2.4.1 MicroRNA-21-3p regulates genes involving in NAFLD progression resulting in a decrease of hepatic lipid contents 79 2.4.2 Berberine regulates regulates lipid metabolic genes 80 2.4.3 Hepatic lipid metabolic pathways are regulated by miR-21-3p 81 2.5 Conclusion 84 References 85 Appendix 1. Berberine-regulated genes amongst the 3 donor PHHs 95 Abbreviations MAT methionine adenosyltransferase SAM S-adenosylmethionine HCC hepatocellular carcinoma BBR berberine DMSO dimethyl sulfoxide miRNA microRNA Ago argonaute qRT-PCR quantitative real-time RT-PCR RIP RNA binding protein immunoprecipitation 3’UTR three prime untranslated region NAFLD nonalchoholic fatty liver disease ACC acetyl-CoA-carboxylas DGAT diglyceride acyltransferase TG triacylglycerol HMCPIS induction qualified human plateable cryopreserved hepatocytes PHHs primary human hepatocytes List of Figures Chapter 1 Figure 1.3-1. Berberine treatment increases the expression of hsa-miR-21-3p in HepG2 cell lines 17 Figure 1.3-2. Berberine treatment slightly increases the promoter activity of MIR21 in HepG2 cells 18 Figure 1.3-3. Berberine increases the interaction between Ago and miR-21-3p 19 Figure 1.3-4. MIR21 is conserved over the mammalian evolution 20 Figure 1.3-5. MAT2A, DIDO1, EEF2K, NBPF8, and TMEM137 are regulated by berberine-induced miR-21-3p 22 Figure 1.3-6. MicroRNA-21-3p and berberine induce differential changes in MAT expression and miR-21-3p up-regulates SAM contents 25 Figure 1.3-7. A dual luciferase reporter assay shows that MAT2A and MAT2B are direct targets of miR-21-3p 29 Figure 1.3-8. MicroRNA-21-3p suppresses growth and induces apoptosis in HepG2 cells 31 Chapter 2 Figure 2.3-1. Berberine treatment consistently increases the expression of hsa-miR-21-3p in primary human hepatocytes among three donors 55 Figure 2.3-2. MicroRNA-21-3p reduces hepatic lipid droplets in primary human hepatocytes, in an oleic acid-induced in vitro hepatic steatosis model, and in HepG2 cells 58 Figure 2.3-3. Hierarchical clustering analysis of gene expression for primary human hepatocytes after treatment for different time with berberine (BBR) or untreated control 64 Figure 2.3-4. Signal Scatter plots of log-intensity of each probe set from the array for berberine treated versus untreated primary human hepatocytes obtained from three donors 65 Figure 2.3-5. Berberine affects expression of lipid metabolic genes in primary human hepatocytes 66 Figure 2.3-6. MicroRNA-21-3p reduces ACACB and ACACA expression leading to decrease of intracellular malonyl-CoA concentrations 69 Figure 2.3-7. MicroRNA-21-3p targets to ACACB exon and destabilizes ACACA mRNA 72 Figure 2.3-8. MiR-21-3p directly reduces the expression of DGAT2 by targeting its 3’ UTRs 75 Figure 2.3-9. Lipid metabolic genes and intracellular malonyl-CoA concentrations are regulated by miR-21-3p in primary human hepatocytes 78 Figure 2.4-1. A schematic model of miR-21-3p regulates hepatic lipid metabolism.83 List of Tables Chapter 2 Table 2.2-1. Primer sequences 53 Table 2.3-1. Berberine-regulated lipid metabolic genes amongst the 3 donor PHHs 62 | |
dc.language.iso | en | |
dc.title | 探討小檗鹼誘導之微小 RNA 於肝細胞之作用機制 | zh_TW |
dc.title | The functional mechanism of berberine-induced microRNA
in hepatocytes | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔡明道,王寬,阮雪芬,施嘉和 | |
dc.subject.keyword | 小檗鹼,微小 RNA,肝癌,甲硫胺酸腺基轉移酵素,脂肪肝,乙醯輔? A 羧化酵素,二脂?甘油?基轉移?, | zh_TW |
dc.subject.keyword | berberine,microRNA,hepatocellular carcinoma,methionine adenosyltransferase,fatty liver disease,acetyl-CoA carboxylase,diglyceride acyltransferase, | en |
dc.relation.page | 119 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2014-01-21 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 4.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。